Clinical Trials Using Anti-OX40 Antibody BMS 986178

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-OX40 Antibody BMS 986178. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and / or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have Spread

    The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and / or Ipilimumab, in patients with solid cancers that are advanced or have spread.
    Location: 4 locations

  • SD-101 and BMS-986178 in Treating Patients with Advanced or Metastatic Solid Malignancies

    This phase I trial studies the side effects of intratumoral injection of SD-101 and BMS-986178 in treating patients with solid malignancies that have spread to other places in the body. Drugs used in chemotherapy, such as SD-101, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with BMS-986178, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving SD-101 and BMS-986178 may work better in treating patients with solid malignancies.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients with Low-Grade B-Cell Non-Hodgkin Lymphomas

    This phase I trial studies the side effects and best dose of TLR9 agonist SD-101 when given together with anti-OX40 antibody BMS 986178 and radiation therapy in treating patients with low-grade B-cell non-Hodgkin lymphomas. TLR9 agonist SD-101 may stimulate the immune system in different ways and stop cancer cells from growing. Immunotherapy with monoclonal antibodies, such as anti-OX40 antibody BMS 986178, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill cancer cells. Giving TLR9 agonist SD-101 together with anti-OX40 antibody BMS 986178 and radiation therapy may work better in treating patients with low-grade B-cell non-Hodgkin lymphomas.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California